Institut D Investigacio Sanitaria Pere Virgili
- Address
- lock Available on a paid plan
Digestive System Diseases
At Institut D Investigacio Sanitaria Pere Virgili, research in Digestive System Diseases focuses on Crohn's disease and related inflammatory bowel complications. The studies are aimed at exploring new treatment options and assessing the safety of innovative approaches for patients with difficult-to-manage intestinal strictures.
- Crohn's disease and inflammatory bowel strictures
- Evaluation of a new cell-based therapy for treatment feasibility and safety
This work reflects a strong clinical interest in improving care for patients with chronic gastrointestinal inflammation and its complications.
Neoplasms
The site also supports research in Neoplasms, with studies centered on advanced tumors. These trials are designed to better understand treatment effectiveness and to estimate outcomes such as overall survival in patients with advanced cancer.
- Advanced tumors
- Assessment of treatment effectiveness and patient survival
This area highlights ongoing efforts to improve cancer care through clinical research in patients with limited treatment options.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Merck Sharp & Dohme LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut D Investigacio Sanitaria Pere Virgili
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded | 1 | Unknown | 2022-10-22 | 2022-10-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.